country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-136893

Copy Link Print Information

SP-6-27

SP-6-27 is a tubulin depolymerizing agent that binds to the colchicine site of β-tubulin. SP-6-27 induces G₂/M cell cycle arrest in ovarian cancer cells. SP-6-27 enhances intrinsic apoptosis in ovarian cancer cells through upregulation of Bax, Apaf-1, caspase-6, caspase-9, and caspase-3. SP-6-27 reduces ovarian cancer cell migration. SP-6-27 inhibits capillary tube formation by human umbilical vein endothelial cells. SP-6-27 shows minimum cytotoxicity to normal ovarian epithelia. SP-6-27 shows enhanced cytotoxicity in chemo-sensitive/resistant ovarian cancer cells when combined with Cisplatin (HY-17394). SP-6-27 can be used for the research of ovarian cancer.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 1384170-58-4
分子式: C₂₄H₂₄N₄O
分子量:384.48

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (279 KB)

SP-6-27 構造式

CAS 番号: 1384170-58-4

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
化学情報
純度とドキュメンテーション
参考文献
Calculators
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

Bax

Caspase 3

Caspase-6

Caspase-9

Caspase アイソフォーム固有の製品をすべて表示 :

Bcl-2 Family アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
A 172	IC₅₀	7.4 nM Compound: 4e	Antiproliferative activity against human A172 cells after 5 days by MTT assay Antiproliferative activity against human A172 cells after 5 days by MTT assay	[PMID: 22608389]
A-375	IC₅₀	0.08 μM Compound: 4e	Antiproliferative activity against human A375 cells after 48 hrs by SRB assay Antiproliferative activity against human A375 cells after 48 hrs by SRB assay	[PMID: 22608389]
Astrocyte	IC₅₀	2033 nM Compound: 4e	Cytotoxicity against mouse primary astrocytes after 5 days by MTT assay Cytotoxicity against mouse primary astrocytes after 5 days by MTT assay	[PMID: 22608389]
LN-18	IC₅₀	13.3 nM Compound: 4e	Antiproliferative activity against human LN18 cells after 5 days by MTT assay Antiproliferative activity against human LN18 cells after 5 days by MTT assay	[PMID: 22608389]
LNCaP	IC₅₀	0.14 μM Compound: 4e	Antiproliferative activity against human LNCAP cells after 96 hrs by SRB assay Antiproliferative activity against human LNCAP cells after 96 hrs by SRB assay	[PMID: 22608389]
PC-3	IC₅₀	0.22 μM Compound: 4e	Antiproliferative activity against human PC3 cells after 96 hrs by SRB assay Antiproliferative activity against human PC3 cells after 96 hrs by SRB assay	[PMID: 22608389]
T98G	IC₅₀	12.5 nM Compound: 4e	Antiproliferative activity against human T98G cells after 5 days by MTT assay Antiproliferative activity against human T98G cells after 5 days by MTT assay	[PMID: 22608389]
U-87MG ATCC	IC₅₀	20.6 nM Compound: 4e	Antiproliferative activity against human U87 cells after 5 days by MTT assay Antiproliferative activity against human U87 cells after 5 days by MTT assay	[PMID: 22608389]
WM164	IC₅₀	0.16 μM Compound: 4e	Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay	[PMID: 22608389]

体外実験

SP-6-27 (0.001-10 μM; 72 h) potently inhibits proliferation in Cisplatin-sensitive and resistant ovarian cancer cells and exhibits minimal cytotoxicity to normal HOSEpiC cells (IC₅₀ = 0.10-0.84 μM for OVCA cells, 83.35 μM for HOSEpiC cells)^[1].
SP-6-27 (0.5 μM; 24 h) disrupts alpha-tubulin and beta-tubulin cytoskeletal structure, reducing microtubule density in ovarian cancer cells^[1].
SP-6-27 (0.5 μM; 48 h) reduces migration in ovarian cancer cells (A2780)^[1].
SP-6-27 (0.5 μM; 24 h) induces G₂-M cell cycle arrest in Cisplatin-sensitive and resistant ovarian cancer cells^[1].
SP-6-27 (0.5 μM; 24-48 h) induces apoptosis in Cisplatin-sensitive and resistant ovarian cancer cells^[1].
SP-6-27 upregulates pro-apoptotic genes (Bax, PAF-1, caspase-9, caspase-6, Caspase-3) and GADD45A in ovarian cancer cells^[1].
SP-6-27 (0.5 μM; 24-48 h) enhances cytotoxicity in Cisplatin-sensitive cells when treated simultaneously with Cisplatin and in Cisplatin-resistant cells when treated sequentially^[1].
SP-6-27 (0.5-1 μM; 24 h) inhibits capillary tube formation by HUVECs, even in the presence of tumor conditioned media^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

cisplatin-sensitive OVCA (A2780, SKOV-3, TOV-112D), cisplatin-resistant OVCA (OVCAR-3, cis-A2780, cis-TOV-112D), HOSEpiC
Concentration:

0.001-10 μM
Incubation Time:

72 h
Result:

Exhibited potent cytotoxicity against Cisplatin-sensitive OVCA cells with a mean IC₅₀ of 0.14 μM and against cisplatin-resistant OVCA cells with a mean IC₅₀ of 0.36 μM; showed minimal cytotoxicity with an IC₅₀ of 83.35 μM in normal HOSEpiC cells.

Cell Migration Assay ^[1]

Cell Line:

A2780 OVCA cells
Concentration:

0.5 μM
Incubation Time:

48 h
Result:

Reduced migration compared to control cells when monitored over 48 h.

Cell Cycle Analysis^[1]

Cell Line:

Cisplatin-sensitive A2780 and Cisplatin-resistant cis-A2780 OVCA cells
Concentration:

0.5 μM
Incubation Time:

24 h
Result:

Caused a complete collapse of cells in G1 phase and a substantial increase in G2-M phase cells: 87.8% of A2780 cells were arrested in G2-M phase (vs. 16.40% in control) and 58.9% of cis-A2780 cells were arrested in G2-M phase (vs. 14.5% in control).

Apoptosis Analysis^[1]

Cell Line:

Cisplatin-sensitive A2780 and Cisplatin-resistant cis-A2780 OVCA cells
Concentration:

0.5 μM
Incubation Time:

24 h (caspase-3 microscopy); 24, 48 h (Annexin V/7-AAD)
Result:

Caused a pronounced increase in Annexin-V positive cells (early/late apoptotic) in both cell types at 24 and 48 h; showed increased cleaved caspase-3 activity in A2780 cells compared to control cells.

化学情報

CAS 番号 1384170-58-4
分子量 384.48
分子式 C₂₄H₂₄N₄O
SMILES

N#CC1=C(OC2=CC(=CC=C2C1C=3C=CC(=C4C=CC=CC43)N(C)C)N(C)C)N
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (279 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Kulshrestha A, et al. Microtubule inhibitor, SP-6-27 inhibits angiogenesis and induces apoptosis in ovarian cancer cells. Oncotarget. 2017;8(40):67017-67028. Published 2017 May 2. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ

Amount: USD 0.00

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
化学情報
純度とドキュメンテーション
参考文献

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

SP-6-27

Caspase アイソフォーム固有の製品をすべて表示

Bcl-2 Family アイソフォーム固有の製品をすべて表示

生物活性

化学情報

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs

SP-6-27 関連分類

HY-136893 関連分類